Skip to main content
Premium Trial:

Request an Annual Quote

Discovery Partners International Completes Acquisition of Xenometrix

NEW YORK, May 9 – Discovery Partners International has completed its acquisition of  gene profiling technology company Xenometrix, the company said Wednesday.

Xenometrix of Boulder, Colo., is the latest addition to Discovery Partners’ drug discovery technology offerings. In February, Discovery Partners signed the initial agreement to acquire Xenometrix for $1.7 million. 

On May 4, Discovery Partners shareholders approved the deal. Under the terms of the agreement, Discovery Partners has agreed to purchase all of Xenometrix’s common stock at a share price of 59 cents per share—a 46 premium over its closing price of 41 cents per share the day before the deal closed. Xenometrix will now be operated as a wholly owned subsidiary of Discovery Partners. 

This acquisition provides Discovery Partners with unfettered access to Xenometrix’s patented gene profiling technology, which Xenometrix has licensed to Affymetrix, Aurora Biosciences, Corning, Gene Logic, GeneTrace, Genometrix, Genzyme, Motorola, Packard, Pfizer, Phase-1, Rosetta Inpharmatics, and GlaxoSmithKline.  

Xenometrix also has proprietary genotoxicity technology that enables high throughput screening for genotoxicity, and its bioinformatics team has been assembling a database of gene profiles for public domain pharmaceuticals.  

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.